How to Estimate the Probability of Tolerance Long-Term in Liver Transplant Recipients.
graft loss
graft rejection
immunosuppression
liver transplantation
operational tolerance
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
16 Oct 2023
16 Oct 2023
Historique:
received:
03
09
2023
revised:
29
09
2023
accepted:
11
10
2023
medline:
28
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
Operational tolerance as the ability to accept the liver transplant without pharmacological immunosuppression is a common phenomenon in the long-term course. However, it is currently underutilized due to a lack of simple diagnostic support and fear of rejection despite its recognized benefits. In the present work, we present a simple score based on clinical parameters to estimate the probability of tolerance. In order to estimate the probability of tolerance, clinical parameters from 82 patients after LT who underwent weaning from the IS for various reasons at our transplant center were extracted from a prospectively organized database and analyzed retrospectively. Univariate testing as well as multivariable logistic regression analysis were performed to assess the association of clinical variables with tolerance in the real-world setting. The most important factors associated with tolerance after multivariable logistic regression were IS monotherapy, male sex, history of hepatocellular carcinoma pretransplant, time since LT, and lack of rejection. These five predictors were retained in an approximate model that could be presented as a simple scoring system to estimate the clinical probability of tolerance or IS dispensability with good predictive performance (AUC = 0.89). In parallel with the existence of a tremendous need for further research on tolerance mechanisms, the presented score, after validation in a larger collective preferably in a multicenter setting, could be easily and safely applied in the real world and already now address all three levels of prevention in LT patients over the long-term course.
Sections du résumé
BACKGROUND
BACKGROUND
Operational tolerance as the ability to accept the liver transplant without pharmacological immunosuppression is a common phenomenon in the long-term course. However, it is currently underutilized due to a lack of simple diagnostic support and fear of rejection despite its recognized benefits. In the present work, we present a simple score based on clinical parameters to estimate the probability of tolerance.
PATIENTS AND METHODS
METHODS
In order to estimate the probability of tolerance, clinical parameters from 82 patients after LT who underwent weaning from the IS for various reasons at our transplant center were extracted from a prospectively organized database and analyzed retrospectively. Univariate testing as well as multivariable logistic regression analysis were performed to assess the association of clinical variables with tolerance in the real-world setting.
RESULTS
RESULTS
The most important factors associated with tolerance after multivariable logistic regression were IS monotherapy, male sex, history of hepatocellular carcinoma pretransplant, time since LT, and lack of rejection. These five predictors were retained in an approximate model that could be presented as a simple scoring system to estimate the clinical probability of tolerance or IS dispensability with good predictive performance (AUC = 0.89).
CONCLUSION
CONCLUSIONS
In parallel with the existence of a tremendous need for further research on tolerance mechanisms, the presented score, after validation in a larger collective preferably in a multicenter setting, could be easily and safely applied in the real world and already now address all three levels of prevention in LT patients over the long-term course.
Identifiants
pubmed: 37892685
pii: jcm12206546
doi: 10.3390/jcm12206546
pmc: PMC10607917
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Liver Transpl. 2016 Nov;22(S1):71-78
pubmed: 27514705
J Hepatol. 2021 Dec;75(6):1409-1419
pubmed: 34437910
Lancet Oncol. 2012 Jan;13(1):e11-22
pubmed: 22047762
Transl Gastroenterol Hepatol. 2017 Oct 12;2:80
pubmed: 29167827
J Hepatol. 1996 Nov;25(5):649-54
pubmed: 8938541
Front Immunol. 2020 Sep 02;11:2155
pubmed: 32983177
Transpl Int. 2018 Dec;31(12):1293-1317
pubmed: 30259574
Liver Transpl. 2017 Oct;23(S1):S85-S88
pubmed: 28779559
Am J Transplant. 2019 May;19(5):1397-1409
pubmed: 30506630
Transplant Proc. 1991 Dec;23(6):3197-9
pubmed: 1721407
J Hepatol. 2001 Jan;34(1):84-91
pubmed: 11211912
Liver Transpl. 2019 Mar;25(3):425-435
pubmed: 30615251
Clin Gastroenterol Hepatol. 2017 Apr;15(4):584-593.e2
pubmed: 27567694
Cancers (Basel). 2021 Mar 31;13(7):
pubmed: 33807392
JAMA. 2012 Jan 18;307(3):283-93
pubmed: 22253395
J Clin Invest. 2008 Aug;118(8):2845-57
pubmed: 18654667
Transplantation. 2022 May 1;106(5):1004-1011
pubmed: 34342962
Transplant Proc. 1993 Feb;25(1 Pt 1):8-12
pubmed: 8438487
Transplantation. 2008 Nov 27;86(10):1370-8
pubmed: 19034005
Vaccines (Basel). 2021 Dec 01;9(12):
pubmed: 34960168
J Clin Invest. 2012 Jan;122(1):368-82
pubmed: 22156196
Transplantation. 2001 Aug 15;72(3):449-54
pubmed: 11502975
Gastroenterology. 2011 Jan;140(1):51-64
pubmed: 21073873
Hepatology. 1997 Mar;25(3):658-63
pubmed: 9049215
J Nephrol. 2017 Dec;30(6):851-857
pubmed: 28317077
Cancers (Basel). 2022 Jun 01;14(11):
pubmed: 35681728
Liver Transpl. 2008 Oct;14(10):1428-36
pubmed: 18825704
JAMA. 2011 Nov 2;306(17):1891-901
pubmed: 22045767
Transplantation. 2019 Sep;103(9):1887-1892
pubmed: 30720688
Hepatology. 2013 Nov;58(5):1824-35
pubmed: 23532679
Hepatology. 1994 Jun;19(6):1513-20
pubmed: 8188183
Transplantation. 2022 Oct 1;106(10):1952-1962
pubmed: 35594482
Liver Transpl. 2017 Dec;23(12):1601-1614
pubmed: 28834221
Cancer. 1991 Nov 15;68(10):2095-100
pubmed: 1655200
Virchows Arch. 2011 May;458(5):511-23
pubmed: 21442288
Am J Transplant. 2007 Feb;7(2):309-19
pubmed: 17241111